Ovarian Carcinoma-associated Antigen (OV632): sc-52353

SANTA CRUZ ®
BIOTECHNOLOGY
The Power to Question

BACKGROUND

Ovarian cancer refers to an abnormal, malignant growth located on the ovaries. Ovarian cancer is disproportionately deadly in part because malignant cells are shed into the naturally occurring fluid in the abdominal cavity. These cells then have the potential to float in this fluid and frequently implant on other abdominal (peritoneal) structures including the uterus, urinary bladder, bowel and lining of the bowel wall. These cells can begin forming new tumor growths before cancer is even diagnosed. Antibodies specific for an Ovarian Carcinoma-associated Antigens are useful in diagnosis and treatment of the cancer. There are many proteins specific to ovarian cancer, for example the human folate receptor-α (FR-α), a folate-binding protein that is selectively overexpressed in Ovarian Carcinoma or CF511, a glycoprotein that is elevated in the serum of many patients with Ovarian Carcinoma.

REFERENCES

1. Horowitz, A.T., et al. 1985. A new human Ovarian Carcinoma cell line: establishment and analysis of tumor-associated markers. Oncology 42: 332-337.

2. Ohkawa, K., et al. 1990. Serum levels and biochemical characteristics of human Ovarian Carcinoma-associated Antigen defined by murine monoclonal antibody, CF511. Br. J. Cancer 60: 953-960.

3. Ohkawa, K., et al. 1991. An evaluation of Ovarian Carcinoma-associated Antigen defined by murine monoclonal antibody CF511 in sera from patients with Ovarian Carcinoma. Br. J. Cancer 64: 259-262.

4. Lamers, C.H., et al. 1992. Optimization of culture of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int. J. Cancer 51: 973-979.

5. Mittal, K.R., et al. 1995. Immunohistochemical profile of ovarian inclusion cysts in patients with and without Ovarian Carcinoma. Histochem. J. 27: 119-122.

6. Schmolling, J., et al. 1997. Anti-TAG-72 antibody B72.3—immunological and clinical effects in Ovarian Carcinoma. Hybridoma 16: 53-58.

7. van Hof, A.C., et al. 1997. Biodistribution of (111)indium-labeled engineered human antibody CTM01 in ovarian cancer patients: influence of protein dose. Cancer Res. 56: 5179-5185.

8. Neglia, F., et al. 1999. DNA vaccination against the ovarian carcinoma-associated Antigen folate receptor α (FRα) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Ther. 6: 349-357.

9. Chang, X.H., et al. 2006. Humoral immune responses induced by anti-idiotypic ant of 6B11scFv/hGM-CSF in BALB/c mice. Chin. Med. J. 119: 131-139.

SOURCE

Ovarian Carcinoma-associated Antigen (OV632) is a mouse monoclonal antibody raised against cyst fluid from a serous cystadenocarcinoma of human origin.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 500 µl ascites containing IgG$_{2b}$ with < 0.1% sodium azide.

APPLICATIONS

Ovarian Carcinoma-associated Antigen (OV632) is recommended for detection of Ovarian Carcinoma-associated Antigen of human origin by immunofluorescence (starting dilution to be determined by researcher, dilution range 1:10-1:200) and flow cytometry [1 µg (approximately 10-20 µl) per 1 x 10^6 cells].

STORAGE

For immediate and continuous use, store at 4° C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.